Company News »

Derma Sciences Names Pharmaceutical Development Leader John Caminis, M.D. as Chief Medical Officer

Business Wire
Share on StockTwits
Published on

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of John Caminis, M.D. to the newly created position of chief medical officer. Dr. Caminis is a seasoned pharmaceutical physician with particular expertise in clinical drug development, and will report to Edward J. Quilty, the company’s chairman and CEO.

“We are fortunate to be welcoming John Caminis to the Derma Sciences executive management team,” said Edward J. Quilty. “He brings exceptional experience and credentials not only in clinical development, but also in fostering relationships with key opinion leaders, submitting regulatory filings and managing contract research organizations. He is charged with overseeing our clinical development, including the execution of our Phase 3 program with DSC127 in diabetic foot ulcer healing as well as the pre-clinical programs for DSC127 including scar prevention and the mitigation of effects from radiation exposure. We are confident that Dr. Caminis will add immediate value to the conduct of the DSC127 program. He will additionally have responsibility for clinical studies on our AMNIO line of amniotic allograft products, as well as oversight of clinical studies that support the marketing of our lead advanced wound care products such as MEDIHONEY and TCC-EZ.”

Dr. Caminis has a wide range of experience in managing the clinical trial process for a multitude of therapeutic indications. Since 2011 he served as senior medical director in the immunology, and later in the bone patient value unit at UCB, a global biopharmaceutical company.

Prior to UCB he was vice president, clinical development at Warner Chilcott (now Actavis), where he supported the integration of clinical development functions subsequent to that company’s acquisition of Proctor & Gamble’s pharmaceuticals business. At Warner Chilcott he planned, designed, developed and oversaw clinical development programs in therapeutic areas such as bone metabolism, urology, dermatology and infectious disease. Earlier in his career Dr. Caminis had roles of increasing responsibility in clinical development and medical affairs programs at small as well as large companies like NPS Pharmaceutical, Novartis Pharmaceuticals and Roche Laboratories. While at NPS, he had a pivotal role in the execution and development of key assets for patients with rare diseases.

“This is an exciting time to be joining Derma Sciences as we pursue a tight, patient focused business strategy and are well-positioned for a greater presence in the growing market of advanced wound care,” said Dr. Caminis. “I look forward to joining an impressive team of dedicated associates and executives to add new perspectives to our clinical efforts and to further build our clinical affairs and development capabilities.”

Dr. Caminis has co-authored numerous conference abstracts and more than 20 publications in peer-reviewed journals. He holds an M.D. degree from the University of Athens School of Medicine in Greece. He served as a clinical research fellow of The McGill Bone Center and has Masters Certification in Project Management from George Washington University School of Business/ESI International.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL(R) and AMNIOMATRIX(R) in the first quarter of 2014. Both products were launched in 2014, and both are included within the Veterans Administration Federal Supply Schedule. AMNIOEXCEL is currently the focus of a randomized clinical trial on the management of Diabetic Foot Ulcers. Derma Sciences’ MEDIHONEY(R) product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ(R) is a gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB(R) for better management of wound exudate, and BIOGUARD(R) for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, a patented active pharmaceutical ingredient (API) which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. DSC127 is also in preclinical testing for scar prevention/reduction and is part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The Company also offers a full product line of traditional dressings.

For more information please visit www.dermasciences.com.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company’s results include, but are not limited to development and commercialization of DSC127, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include but are not limited to, those discussed in the Company’s filings with the U.S. Securities and Exchange Commission.

Share on StockTwits